Clinical trials: Allergic Conjunctivitis
Conjunctivitis, Vernal
Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)
The primary objective of this study is: To assess the efficacy of Nova22007, a cyclosporine A (CsA), 0.05% and 0.1% versus vehicle in patients with vernal keratoconjunctivitis (VKC) after a 4-week treatment period.
- Trial name
- NCT00328653
- Testing
- Cyclosporine NOVA22007 0.05%, Cyclosporine NOVA22007 0.1%, Vehicle
- Where
- France
- Volunteers
- 118 people
- Sponsor
- Santen SAS
Conjunctivitis, Allergic
Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis
The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a…
- Trial name
- NCT01289431
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
The purpose of the study is to demonstrate safety and efficacy of DE-114 ophthalmic solution compared to its Placebo and Olopatadine hydrochloride 0.1% ophthalmic solution in patients with allergic conjunctivitis.
- Trial name
- NCT01363700
- Testing
- DE-114 ophthalmic solution, Olopatadine Hydrochloride 0.1% Ophthalmic Solution
- Where
- Japan
- Volunteers
- 87 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Allergic Conjunctivitis
The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer
The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye drop on the quality of your tears.
- Trial name
- NCT01346371
- Testing
- Refresh Tears 0.5% Lubricant Eye Drops, Bepreve 1.5% Ophthalmic Solution
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Minnesota Eye Consultants, P.A.
Allergic Conjunctivitis
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.
- Trial name
- NCT05815758
- Testing
- Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
- Where
- 7 sites in United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Conjunctivitis, Allergic
A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber
An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)
- Trial name
- NCT03709121
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Conjunctivitis
Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis
The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis.
- Trial name
- NCT00534794
- Testing
- Elestat, Pataday
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Merck Sharp & Dohme LLC
Atopic Disease (Including Allergic Conjunctivitis)
A Multi-Center Study Evaluating the Safety of AC-170 0.24%
The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).
- Trial name
- NCT02132169
- Testing
- Drug: AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 512 people
- Sponsor
- Aciex Therapeutics, Inc.
Conjunctivitis, Allergic
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT01470118
- Testing
- alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Allergan
Allergic Conjunctivitis
Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT00882687
- Testing
- Lifitegrast
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Shire
Chronic Allergic Conjunctivitis
OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of…
- Trial name
- NCT02062905
- Testing
- Dexamethasone
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ocular Therapeutix, Inc.
Allergic Conjunctivitis
Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model
The purpose of this study is to evaluate the efficacy of AC-150 compared to vehicle and its components in the prevention of the signs and symptoms of allergic conjunctivitis in Enviro-CAC™ Model.
- Trial name
- NCT01134328
- Testing
- AC-150 Combo, AC-150A 0.1%, AC-150B 0.005%
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Aciex Therapeutics, Inc.
Chronic Allergic Conjunctivitis
Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory…
- Trial name
- NCT01730872
- Testing
- Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- ORA, Inc.
Allergic Conjunctivitis
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen…
- Trial name
- NCT00770133
- Testing
- Ketotifen/naphazoline, Naphazoline, Ketotifen
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT03479307
- Testing
- Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 228 people
- Sponsor
- Faes Farma, S.A.
Rhinitis; Allergic, With Asthma, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00783198
- Testing
- SCH 39641 6 Amb a 1-U, SCH 39641 12 Amb a 1-U
- Volunteers
- 565 people
- Sponsor
- ALK-Abelló A/S
Allergic Conjunctivitis
Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis
The purpose of this study is to evaluate two investigational ophthalmic solutions for reduction in ocular redness in subjects with allergic conjunctivitis.
- Trial name
- NCT02079649
- Testing
- AL-53817 Ophthalmic Solution, 0.1%, AL-78843 Ophthalmic Solution, 0.03%, Dexamethasone Ophthalmic Suspension, 0.1%
- Volunteers
- 224 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
AGN-229666 for the Treatment of Allergic Conjunctivitis
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.
- Trial name
- NCT01754766
- Testing
- AGN-229666, vehicle of AGN-229666
- Where
- Japan
- Volunteers
- 90 people
- Sponsor
- Allergan
Allergic Conjunctivitis
A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT04050865
- Testing
- Dexamethasone, 0.4mg
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- Ocular Therapeutix, Inc.
Allergic Conjunctivitis
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
The present study will test if administration of different concentrations of 1334H eyedrops will be effective in treatment of allergic conjunctivitis in people with 10 yrs of age or older.
- Trial name
- NCT01320553
- Testing
- SPARC1102 I, SPARC1102 II, SPARC1102 III
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Sun Pharma Advanced Research Company Limited